{"id":754769,"date":"2023-05-04T07:52:41","date_gmt":"2023-05-04T11:52:41","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/silence-therapeutics-achieves-10-million-milestone-payment-from-astrazeneca-collaboration\/"},"modified":"2023-05-04T07:52:41","modified_gmt":"2023-05-04T11:52:41","slug":"silence-therapeutics-achieves-10-million-milestone-payment-from-astrazeneca-collaboration","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/silence-therapeutics-achieves-10-million-milestone-payment-from-astrazeneca-collaboration\/","title":{"rendered":"Silence Therapeutics Achieves $10 Million Milestone Payment from AstraZeneca Collaboration"},"content":{"rendered":"<p>        <!--.bwalignc { text-align: center; list-style-position: inside }body {font:normal small Arial,Helvetica,sans-serif;color:#000;background-color:#fff;padding:24px;margin:0;} a img {border:0;} h3 {font-size:medium;color:#000;margin:0 0 1em 0; text-align:center;}-->  <\/p>\n<p class=\"bwalignc\">\nSilence Therapeutics Achieves $10 Million Milestone Payment from AstraZeneca Collaboration<\/p>\n<p>LONDON&#8211;(<a href=\"http:\/\/www.businesswire.com\">BUSINESS WIRE<\/a>)&#8211;<br \/>\nSilence Therapeutics plc, Nasdaq: SLN (\u201cSilence\u201d or \u201cthe Company\u201d), an experienced and innovative biotechnology company committed to transforming people\u2019s lives by silencing diseases through precision engineered medicines, today announced that AstraZeneca has nominated the first product candidate under its siRNA (short interfering RNA) collaboration and will pay Silence a $10 million option fee to advance development on an undisclosed program.<\/p>\n<p>\n\u201cWe are very pleased to announce this important milestone in our collaboration with AstraZeneca,\u201d said Craig Tooman, President and CEO of Silence. \u201cWe expect this positive momentum to continue as we advance the current program and initiate additional targets. We look forward to communicating more as we achieve additional milestones in the collaboration.\u201d<\/p>\n<p>\nRegina Fritsche Danielson, SVP, Early Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&amp;D, AstraZeneca said, \u201cThis is a very exciting first milestone in our long-term collaboration with Silence Therapeutics and we look forward to continued successes across our ongoing projects to address cardiovascular, renal and metabolic diseases.\u201d<\/p>\n<p>\nSilence and AstraZeneca initiated a multi-target collaboration in March 2020 focused on using Silence\u2019s proprietary mRNAi GOLD\u2122 platform to develop siRNA therapeutics for cardiovascular, renal, metabolic and respiratory diseases. Under the agreement, AstraZeneca will pay Silence an option fee of $10 million for each selected target at the point of candidate nomination. The deal covers up to ten targets. For each target selected, Silence is eligible for up to $140 million in development milestones and up to $250 million in commercialization milestones as well as tiered royalties on net sales ranging from high single digit to low double digit.<\/p>\n<p><b>About Silence Therapeutics<br \/>\n<br \/><\/b>Silence Therapeutics is developing a new generation of medicines by harnessing the body&#8217;s natural mechanism of RNA interference, or RNAi, to inhibit the expression of specific target genes thought to play a role in the pathology of diseases with significant unmet need. Silence&#8217;s proprietary mRNAi GOLD\u2122 platform can be used to create siRNAs (short interfering RNAs) that precisely target and silence disease-associated genes in the liver, which represents a substantial opportunity. Silence&#8217;s wholly owned product candidates include SLN360 designed to address the high and prevalent unmet medical need in reducing cardiovascular risk in people born with high levels of lipoprotein(a) and SLN124 designed to address hematological diseases. Silence also maintains ongoing research and development collaborations with AstraZeneca, Mallinckrodt Pharmaceuticals, and Hansoh Pharma, among others. For more information, please visit <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.globenewswire.com%2FTracker%3Fdata%3DseWLk0Tijvb87pYYtHlfJBSxU-O0-uhbTanKn5RhA2rNJ_BGh5GwtTTFOolm5n2IgC_sZlfXwUjJf1q1KZQGqwMF9rpkGI9IXJVi3CKfXBhC7d9RDrI9bKFnvBa_D7yENo8TBNOrH81g_BaE5LBZTg%3D%3D&amp;esheet=53393077&amp;newsitemid=20230504005217&amp;lan=en-US&amp;anchor=https%3A%2F%2Fwww.silence-therapeutics.com%2F&amp;index=1&amp;md5=3a69320c54c328809c7e92a98e08d6d2\">https:\/\/www.silence-therapeutics.com\/<\/a>.<\/p>\n<p><b>Forward-Looking Statements<br \/>\n<br \/><\/b>Certain statements made in this announcement are forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 and other securities laws, including with respect to the Company\u2019s cash runway and forecast operating cash flow, the Company\u2019s clinical and commercial prospects, regulatory approvals of the Company\u2019s product candidates, potential partnerships or collaborations or payments under new and existing collaborations, the initiation or completion of the Company\u2019s clinical trials and the anticipated timing or outcomes of data reports from the Company\u2019s clinical trials. These forward-looking statements are not historical facts but rather are based on the Company&#8217;s current assumptions, beliefs, expectations, estimates and projections about its industry. Words such as \u201canticipate,\u201d \u201cexpect,\u201d \u201cintend,\u201d \u201cplan,\u201d \u201cbelieve,\u201d \u201cseek,\u201d \u201cestimate,\u201d and similar expressions are intended to identify forward-looking statements. These statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties, and other factors, some of which are beyond the Company&#8217;s control, are difficult to predict, and could cause actual results to differ materially from those expressed or forecasted in the forward-looking statements, including those risks identified in the Company\u2019s most recent Admission Document and its Annual Report on Form 20-F filed with the U.S. Securities and Exchange Commission on March 15, 2023. The Company cautions security holders and prospective security holders not to place undue reliance on these forward-looking statements, which reflect the view of the Company only as of the date of this announcement. The forward-looking statements made in this announcement relate only to events as of the date on which the statements are made. The Company will not undertake any obligation to release publicly any revisions or updates to these forward-looking statements to reflect events, circumstances, or unanticipated events occurring after the date of this announcement except as required by law or by any appropriate regulatory authority.<\/p>\n<p><img decoding=\"async\" alt=\"\" src=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20230504005217r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" style=\"width:0;height:0\" \/><span class=\"bwct31415\" \/><\/p>\n<p id=\"mmgallerylink\"><span id=\"mmgallerylink-phrase\">View source version on businesswire.com: <\/span><span id=\"mmgallerylink-link\"><a href=\"https:\/\/www.businesswire.com\/news\/home\/20230504005217\/en\/\" rel=\"nofollow\">https:\/\/www.businesswire.com\/news\/home\/20230504005217\/en\/<\/a><\/span><\/p>\n<p><b>Inquiries:<br \/>\n<br \/>Silence Therapeutics plc<br \/>\n<\/b><br \/>Gem Hopkins, Head of IR and Corporate Communications<br \/>\n<br \/><a rel=\"nofollow\" href=\"mailto:ir@silence-therapeutics.com\">ir@silence-therapeutics.com<br \/>\n<\/a><br \/>Tel: +1 (646) 637-3208<\/p>\n<p><b>KEYWORDS:<\/b> North America United States Ireland United Kingdom Europe<\/p>\n<p><b>INDUSTRY KEYWORDS:<\/b> Health Other Science General Health Research Science Pharmaceutical Biotechnology<\/p>\n<p><b>MEDIA:<\/b><\/p>\n<table cellpadding=\"3\" cellspacing=\"3\">\n<tr>\n<td><font face=\"Arial\" size=\"2\"><b>Logo<\/b><\/font><\/td>\n<\/tr>\n<tr>\n<td><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20230504005217\/en\/1783063\/3\/Silence-Logo-FINAL-rgb.jpg\" alt=\"Logo\" \/><\/td>\n<\/tr>\n<tr>\n<td><font face=\"Arial\" size=\"2\"><\/font><\/td>\n<\/tr>\n<\/table>\n","protected":false},"excerpt":{"rendered":"<p>Silence Therapeutics Achieves $10 Million Milestone Payment from AstraZeneca Collaboration LONDON&#8211;(BUSINESS WIRE)&#8211; Silence Therapeutics plc, Nasdaq: SLN (\u201cSilence\u201d or \u201cthe Company\u201d), an experienced and innovative biotechnology company committed to transforming people\u2019s lives by silencing diseases through precision engineered medicines, today announced that AstraZeneca has nominated the first product candidate under its siRNA (short interfering RNA) collaboration and will pay Silence a $10 million option fee to advance development on an undisclosed program. \u201cWe are very pleased to announce this important milestone in our collaboration with AstraZeneca,\u201d said Craig Tooman, President and CEO of Silence. \u201cWe expect this positive momentum to continue as we advance the current program and initiate additional targets. We look forward to communicating more as we achieve &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/silence-therapeutics-achieves-10-million-milestone-payment-from-astrazeneca-collaboration\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Silence Therapeutics Achieves $10 Million Milestone Payment from AstraZeneca Collaboration&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-754769","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Silence Therapeutics Achieves $10 Million Milestone Payment from AstraZeneca Collaboration - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/silence-therapeutics-achieves-10-million-milestone-payment-from-astrazeneca-collaboration\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Silence Therapeutics Achieves $10 Million Milestone Payment from AstraZeneca Collaboration - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Silence Therapeutics Achieves $10 Million Milestone Payment from AstraZeneca Collaboration LONDON&#8211;(BUSINESS WIRE)&#8211; Silence Therapeutics plc, Nasdaq: SLN (\u201cSilence\u201d or \u201cthe Company\u201d), an experienced and innovative biotechnology company committed to transforming people\u2019s lives by silencing diseases through precision engineered medicines, today announced that AstraZeneca has nominated the first product candidate under its siRNA (short interfering RNA) collaboration and will pay Silence a $10 million option fee to advance development on an undisclosed program. \u201cWe are very pleased to announce this important milestone in our collaboration with AstraZeneca,\u201d said Craig Tooman, President and CEO of Silence. \u201cWe expect this positive momentum to continue as we advance the current program and initiate additional targets. We look forward to communicating more as we achieve &hellip; Continue reading &quot;Silence Therapeutics Achieves $10 Million Milestone Payment from AstraZeneca Collaboration&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/silence-therapeutics-achieves-10-million-milestone-payment-from-astrazeneca-collaboration\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2023-05-04T11:52:41+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20230504005217r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/silence-therapeutics-achieves-10-million-milestone-payment-from-astrazeneca-collaboration\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/silence-therapeutics-achieves-10-million-milestone-payment-from-astrazeneca-collaboration\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Silence Therapeutics Achieves $10 Million Milestone Payment from AstraZeneca Collaboration\",\"datePublished\":\"2023-05-04T11:52:41+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/silence-therapeutics-achieves-10-million-milestone-payment-from-astrazeneca-collaboration\\\/\"},\"wordCount\":779,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/silence-therapeutics-achieves-10-million-milestone-payment-from-astrazeneca-collaboration\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20230504005217r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/silence-therapeutics-achieves-10-million-milestone-payment-from-astrazeneca-collaboration\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/silence-therapeutics-achieves-10-million-milestone-payment-from-astrazeneca-collaboration\\\/\",\"name\":\"Silence Therapeutics Achieves $10 Million Milestone Payment from AstraZeneca Collaboration - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/silence-therapeutics-achieves-10-million-milestone-payment-from-astrazeneca-collaboration\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/silence-therapeutics-achieves-10-million-milestone-payment-from-astrazeneca-collaboration\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20230504005217r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"datePublished\":\"2023-05-04T11:52:41+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/silence-therapeutics-achieves-10-million-milestone-payment-from-astrazeneca-collaboration\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/silence-therapeutics-achieves-10-million-milestone-payment-from-astrazeneca-collaboration\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/silence-therapeutics-achieves-10-million-milestone-payment-from-astrazeneca-collaboration\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20230504005217r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"contentUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20230504005217r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/silence-therapeutics-achieves-10-million-milestone-payment-from-astrazeneca-collaboration\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Silence Therapeutics Achieves $10 Million Milestone Payment from AstraZeneca Collaboration\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Silence Therapeutics Achieves $10 Million Milestone Payment from AstraZeneca Collaboration - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/silence-therapeutics-achieves-10-million-milestone-payment-from-astrazeneca-collaboration\/","og_locale":"en_US","og_type":"article","og_title":"Silence Therapeutics Achieves $10 Million Milestone Payment from AstraZeneca Collaboration - Market Newsdesk","og_description":"Silence Therapeutics Achieves $10 Million Milestone Payment from AstraZeneca Collaboration LONDON&#8211;(BUSINESS WIRE)&#8211; Silence Therapeutics plc, Nasdaq: SLN (\u201cSilence\u201d or \u201cthe Company\u201d), an experienced and innovative biotechnology company committed to transforming people\u2019s lives by silencing diseases through precision engineered medicines, today announced that AstraZeneca has nominated the first product candidate under its siRNA (short interfering RNA) collaboration and will pay Silence a $10 million option fee to advance development on an undisclosed program. \u201cWe are very pleased to announce this important milestone in our collaboration with AstraZeneca,\u201d said Craig Tooman, President and CEO of Silence. \u201cWe expect this positive momentum to continue as we advance the current program and initiate additional targets. We look forward to communicating more as we achieve &hellip; Continue reading \"Silence Therapeutics Achieves $10 Million Milestone Payment from AstraZeneca Collaboration\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/silence-therapeutics-achieves-10-million-milestone-payment-from-astrazeneca-collaboration\/","og_site_name":"Market Newsdesk","article_published_time":"2023-05-04T11:52:41+00:00","og_image":[{"url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20230504005217r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/silence-therapeutics-achieves-10-million-milestone-payment-from-astrazeneca-collaboration\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/silence-therapeutics-achieves-10-million-milestone-payment-from-astrazeneca-collaboration\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Silence Therapeutics Achieves $10 Million Milestone Payment from AstraZeneca Collaboration","datePublished":"2023-05-04T11:52:41+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/silence-therapeutics-achieves-10-million-milestone-payment-from-astrazeneca-collaboration\/"},"wordCount":779,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/silence-therapeutics-achieves-10-million-milestone-payment-from-astrazeneca-collaboration\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20230504005217r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/silence-therapeutics-achieves-10-million-milestone-payment-from-astrazeneca-collaboration\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/silence-therapeutics-achieves-10-million-milestone-payment-from-astrazeneca-collaboration\/","name":"Silence Therapeutics Achieves $10 Million Milestone Payment from AstraZeneca Collaboration - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/silence-therapeutics-achieves-10-million-milestone-payment-from-astrazeneca-collaboration\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/silence-therapeutics-achieves-10-million-milestone-payment-from-astrazeneca-collaboration\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20230504005217r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","datePublished":"2023-05-04T11:52:41+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/silence-therapeutics-achieves-10-million-milestone-payment-from-astrazeneca-collaboration\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/silence-therapeutics-achieves-10-million-milestone-payment-from-astrazeneca-collaboration\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/silence-therapeutics-achieves-10-million-milestone-payment-from-astrazeneca-collaboration\/#primaryimage","url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20230504005217r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","contentUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20230504005217r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/silence-therapeutics-achieves-10-million-milestone-payment-from-astrazeneca-collaboration\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Silence Therapeutics Achieves $10 Million Milestone Payment from AstraZeneca Collaboration"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/754769","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=754769"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/754769\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=754769"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=754769"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=754769"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}